On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

Sanofi reported third-quarter earnings and sales that beat analysts' expectations, boosted by earlier-than-anticipated deliveries of flu and respiratory syncytial virus vaccines and growing demand for ...

French Economy, Finance and Industry Minister Antoine Armand attends a joint press conference on the government's role ...

SALES FORECAST: The Paris-based group's sales are forecast at 12.63 billion euros, according to Visible Alpha. That compares with 11.96 billion euros for the same period the year before. As of ...

(Sebastian Guth, 10/16) Emmanuel Macron’s administration has agreed to take a 1%-2% stake in Sanofi SA’s consumer-health unit Opella to sugar the pill of a US private equity takeover, seen as a ...

Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...

Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating yesterday. David Risinger has ...

The US buyout firm is pairing with the French pharma giant to buy out its consumer unit. Success here requires much more than ...

PARIS (Reuters) -French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its ...

Recent health news highlights include a CDC team assessing bird flu in Washington state farm workers, CVS's leadership change ...

French drama over sovereign paracetamol is really about a deeper ailment: underinvestment.